本帖最后由 老马 于 2013-3-13 13:43 编辑 - W. l+ ~8 |: {( S1 Q( p8 B+ @* U
8 o9 x1 a; k' Z健择（吉西他滨）+顺铂+阿瓦斯汀: u" S& s& e! h5 X* |$ ~5 M7 k. u* X
Gemzar +Cisplatin + Avastin
" O, ]" m a* Hhttp://annonc.oxfordjournals.org/content/21/9/1804.full2 u; E f% M( I4 f, W; T: t
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) x+ n! q# i; X Z! i# ^5 oPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* g8 W- V% ?- Z! aResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ( D2 _. J; Y- Z: F4 `
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 266)
% b8 s7 k, |9 E% N
华为网盘附件： Q8 x/ n' n- [. R/ C. b
【华为网盘】ava.JPG) G7 z# X0 o5 O4 r6 Y. _9 l
|
显身卡
